Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:ALOG's Cash to Debt is ranked higher than
98% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. NAS:ALOG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:ALOG' s Cash to Debt Range Over the Past 10 Years
Min: 2.44  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.84
NAS:ALOG's Equity to Asset is ranked higher than
85% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:ALOG: 0.84 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ALOG' s Equity to Asset Range Over the Past 10 Years
Min: 0.72  Med: 0.83 Max: 0.88
Current: 0.84
0.72
0.88
Interest Coverage No Debt
NAS:ALOG's Interest Coverage is ranked higher than
97% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NAS:ALOG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ALOG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 9.17
M-Score: -2.64
WACC vs ROIC
7.85%
4.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.95
NAS:ALOG's Operating margin (%) is ranked higher than
57% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. NAS:ALOG: 4.95 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ALOG' s Operating margin (%) Range Over the Past 10 Years
Min: -1.06  Med: 5.38 Max: 8.24
Current: 4.95
-1.06
8.24
Net-margin (%) 2.38
NAS:ALOG's Net-margin (%) is ranked higher than
57% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. NAS:ALOG: 2.38 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ALOG' s Net-margin (%) Range Over the Past 10 Years
Min: 0.94  Med: 5.08 Max: 8.34
Current: 2.38
0.94
8.34
ROE (%) 2.29
NAS:ALOG's ROE (%) is ranked higher than
56% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. NAS:ALOG: 2.29 )
Ranked among companies with meaningful ROE (%) only.
NAS:ALOG' s ROE (%) Range Over the Past 10 Years
Min: 0.9  Med: 5 Max: 9.9
Current: 2.29
0.9
9.9
ROA (%) 1.92
NAS:ALOG's ROA (%) is ranked higher than
62% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. NAS:ALOG: 1.92 )
Ranked among companies with meaningful ROA (%) only.
NAS:ALOG' s ROA (%) Range Over the Past 10 Years
Min: 0.76  Med: 4.19 Max: 7.98
Current: 1.92
0.76
7.98
ROC (Joel Greenblatt) (%) 8.58
NAS:ALOG's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. NAS:ALOG: 8.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ALOG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2.21  Med: 11.09 Max: 18.74
Current: 8.58
-2.21
18.74
Revenue Growth (3Y)(%) -2.70
NAS:ALOG's Revenue Growth (3Y)(%) is ranked lower than
64% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. NAS:ALOG: -2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ALOG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.4  Med: 3.8 Max: 15.9
Current: -2.7
-10.4
15.9
EBITDA Growth (3Y)(%) -8.50
NAS:ALOG's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NAS:ALOG: -8.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ALOG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.1  Med: -2.2 Max: 62.7
Current: -8.5
-41.1
62.7
EPS Growth (3Y)(%) -27.10
NAS:ALOG's EPS Growth (3Y)(%) is ranked lower than
79% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. NAS:ALOG: -27.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ALOG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56  Med: -8 Max: 127.6
Current: -27.1
-56
127.6
» NAS:ALOG's 10-Y Financials

Financials (Next Earnings Date: 2016-12-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ALOG Guru Trades in Q4 2015

Jim Simons 21,754 sh (+127.70%)
Richard Snow 184,779 sh (+16.77%)
NWQ Managers 508,722 sh (+5.82%)
Mariko Gordon 557,904 sh (+4.93%)
Chuck Royce 542,745 sh (+0.20%)
» More
Q1 2016

ALOG Guru Trades in Q1 2016

Joel Greenblatt 35,680 sh (New)
NWQ Managers 544,777 sh (+7.09%)
Chuck Royce 565,701 sh (+4.23%)
Mariko Gordon 578,814 sh (+3.75%)
Jim Simons 19,800 sh (-8.98%)
Richard Snow 139,590 sh (-24.46%)
» More
Q2 2016

ALOG Guru Trades in Q2 2016

Joel Greenblatt 92,284 sh (+158.64%)
Chuck Royce 580,101 sh (+2.55%)
NWQ Managers 547,037 sh (+0.41%)
Jim Simons Sold Out
Mariko Gordon 567,408 sh (-1.97%)
Richard Snow 128,985 sh (-7.60%)
» More
Q3 2016

ALOG Guru Trades in Q3 2016

Chuck Royce 588,851 sh (+1.51%)
NWQ Managers 517,550 sh (-5.39%)
Richard Snow 97,775 sh (-24.20%)
Mariko Gordon 416,175 sh (-26.65%)
Joel Greenblatt 55,449 sh (-39.91%)
» More
» Details

Insider Trades

Latest Guru Trades with ALOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:MYGN, NAS:ABAX, NAS:KANG, NAS:AXDX, NAS:GHDX, NAS:FMI, NAS:MEDP, NAS:QDEL, NAS:NEO, NAS:VIVO, NYSE:ARA, NAS:EXAS, NAS:NTRA, NAS:BEAT, NAS:NRCIA, NAS:NVDQ, NAS:HSKA, NAS:LNTH, NAS:ONVO, NAS:SRDX » details
Traded in other countries:AJM.Germany,
Analogic Corp is a technology company that designs and manufactures medical imaging ultrasound and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users in the healthcare and airport security markets.

Analogic Corporation was incorporated in the Commonwealth of Massachusetts in November 1967. The company is a technology company that designs and manufactures medical imaging and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users mainly in the healthcare and airport security markets. The Company's operating segments are Ultrasound, Medical Imaging, and Security and Detection. The Ultrasound segment provides ultrasound guidance systems for the urology and surgery markets and is expanding into point of care areas such as anesthesia and emergency medicine. The Medical Imaging segment provides critical enabling medical imaging systems and subsystems for computed tomography, or CT, magnetic resonance imaging, or MRI and high-resolution digital mammography systems. The Security and Detection segment designs and manufactures automated threat detection systems for aviation baggage inspection applications utilizing CT technology. Its geographical areas include United states, Japan, Germany, Netherlands and others.

Ratios

vs
industry
vs
history
P/E(ttm) 94.76
ALOG's P/E(ttm) is ranked lower than
95% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. ALOG: 94.76 )
Ranked among companies with meaningful P/E(ttm) only.
ALOG' s P/E(ttm) Range Over the Past 10 Years
Min: 10.79  Med: 32.94 Max: 148.85
Current: 94.76
10.79
148.85
Forward P/E 22.62
ALOG's Forward P/E is ranked lower than
58% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.19 vs. ALOG: 22.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 94.76
ALOG's PE(NRI) is ranked lower than
95% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. ALOG: 94.76 )
Ranked among companies with meaningful PE(NRI) only.
ALOG' s PE(NRI) Range Over the Past 10 Years
Min: 15.08  Med: 34.01 Max: 178.18
Current: 94.76
15.08
178.18
Price/Owner Earnings (ttm) 296.22
ALOG's Price/Owner Earnings (ttm) is ranked lower than
97% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.10 vs. ALOG: 296.22 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALOG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.84  Med: 54.18 Max: 839.04
Current: 296.22
12.84
839.04
P/B 2.14
ALOG's P/B is ranked higher than
73% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. ALOG: 2.14 )
Ranked among companies with meaningful P/B only.
ALOG' s P/B Range Over the Past 10 Years
Min: 0.82  Med: 1.83 Max: 2.53
Current: 2.14
0.82
2.53
P/S 2.27
ALOG's P/S is ranked higher than
62% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ALOG: 2.27 )
Ranked among companies with meaningful P/S only.
ALOG' s P/S Range Over the Past 10 Years
Min: 0.78  Med: 1.8 Max: 3.09
Current: 2.27
0.78
3.09
PFCF 57.45
ALOG's PFCF is ranked lower than
81% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.06 vs. ALOG: 57.45 )
Ranked among companies with meaningful PFCF only.
ALOG' s PFCF Range Over the Past 10 Years
Min: 13.87  Med: 33.95 Max: 169.1
Current: 57.45
13.87
169.1
POCF 34.57
ALOG's POCF is ranked lower than
80% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.55 vs. ALOG: 34.57 )
Ranked among companies with meaningful POCF only.
ALOG' s POCF Range Over the Past 10 Years
Min: 9.02  Med: 21.66 Max: 81.55
Current: 34.57
9.02
81.55
EV-to-EBIT 40.23
ALOG's EV-to-EBIT is ranked lower than
80% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. ALOG: 40.23 )
Ranked among companies with meaningful EV-to-EBIT only.
ALOG' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.6  Med: 24.9 Max: 388.6
Current: 40.23
-121.6
388.6
EV-to-EBITDA 21.05
ALOG's EV-to-EBITDA is ranked lower than
63% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. ALOG: 21.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALOG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9  Med: 15.2 Max: 48.4
Current: 21.05
5.9
48.4
PEG 28.41
ALOG's PEG is ranked lower than
100% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ALOG: 28.41 )
Ranked among companies with meaningful PEG only.
ALOG' s PEG Range Over the Past 10 Years
Min: 0.79  Med: 2.62 Max: 356.36
Current: 28.41
0.79
356.36
Shiller P/E 45.99
ALOG's Shiller P/E is ranked lower than
66% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.25 vs. ALOG: 45.99 )
Ranked among companies with meaningful Shiller P/E only.
ALOG' s Shiller P/E Range Over the Past 10 Years
Min: 15.43  Med: 35.82 Max: 53.68
Current: 45.99
15.43
53.68
Current Ratio 4.96
ALOG's Current Ratio is ranked higher than
80% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ALOG: 4.96 )
Ranked among companies with meaningful Current Ratio only.
ALOG' s Current Ratio Range Over the Past 10 Years
Min: 2.92  Med: 4.97 Max: 6.99
Current: 4.96
2.92
6.99
Quick Ratio 3.10
ALOG's Quick Ratio is ranked higher than
64% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ALOG: 3.10 )
Ranked among companies with meaningful Quick Ratio only.
ALOG' s Quick Ratio Range Over the Past 10 Years
Min: 2.33  Med: 3.62 Max: 5.94
Current: 3.1
2.33
5.94
Days Inventory 188.75
ALOG's Days Inventory is ranked lower than
83% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. ALOG: 188.75 )
Ranked among companies with meaningful Days Inventory only.
ALOG' s Days Inventory Range Over the Past 10 Years
Min: 92.53  Med: 118.65 Max: 188.75
Current: 188.75
92.53
188.75
Days Sales Outstanding 80.63
ALOG's Days Sales Outstanding is ranked lower than
69% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. ALOG: 80.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALOG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.76  Med: 68.08 Max: 80.63
Current: 80.63
58.76
80.63
Days Payable 37.15
ALOG's Days Payable is ranked lower than
69% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. ALOG: 37.15 )
Ranked among companies with meaningful Days Payable only.
ALOG' s Days Payable Range Over the Past 10 Years
Min: 29.72  Med: 36.48 Max: 45.64
Current: 37.15
29.72
45.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.44
ALOG's Dividend Yield is ranked lower than
81% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ALOG: 0.44 )
Ranked among companies with meaningful Dividend Yield only.
ALOG' s Dividend Yield Range Over the Past 10 Years
Min: 0.41  Med: 0.62 Max: 1.6
Current: 0.44
0.41
1.6
Dividend Payout 0.42
ALOG's Dividend Payout is ranked lower than
60% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.25 vs. ALOG: 0.42 )
Ranked among companies with meaningful Dividend Payout only.
ALOG' s Dividend Payout Range Over the Past 10 Years
Min: 0.08  Med: 0.23 Max: 1.38
Current: 0.42
0.08
1.38
Forward Dividend Yield 0.44
ALOG's Forward Dividend Yield is ranked lower than
84% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.22 vs. ALOG: 0.44 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.43
ALOG's Yield on cost (5-Year) is ranked lower than
85% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ALOG: 0.43 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALOG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.41  Med: 0.62 Max: 1.6
Current: 0.43
0.41
1.6
3-Year Average Share Buyback Ratio -0.40
ALOG's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. ALOG: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALOG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: -0.4 Max: 2.8
Current: -0.4
-1.6
2.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 65.84
ALOG's Price/Net Cash is ranked lower than
91% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.60 vs. ALOG: 65.84 )
Ranked among companies with meaningful Price/Net Cash only.
ALOG' s Price/Net Cash Range Over the Past 10 Years
Min: 3.17  Med: 8.54 Max: 75.15
Current: 65.84
3.17
75.15
Price/Net Current Asset Value 3.90
ALOG's Price/Net Current Asset Value is ranked higher than
79% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. ALOG: 3.90 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALOG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.88  Med: 2.69 Max: 4.03
Current: 3.9
1.88
4.03
Price/Tangible Book 2.71
ALOG's Price/Tangible Book is ranked higher than
72% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. ALOG: 2.71 )
Ranked among companies with meaningful Price/Tangible Book only.
ALOG' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.39  Med: 1.93 Max: 2.81
Current: 2.71
1.39
2.81
Price/Projected FCF 1.73
ALOG's Price/Projected FCF is ranked higher than
54% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. ALOG: 1.73 )
Ranked among companies with meaningful Price/Projected FCF only.
ALOG' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.04  Med: 1.36 Max: 2.06
Current: 1.73
1.04
2.06
Price/DCF (Earnings Based) 4.56
ALOG's Price/DCF (Earnings Based) is ranked lower than
88% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.02 vs. ALOG: 4.56 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.24
ALOG's Price/Median PS Value is ranked lower than
74% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. ALOG: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
ALOG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.69  Med: 0.99 Max: 1.51
Current: 1.24
0.69
1.51
Price/Graham Number 3.37
ALOG's Price/Graham Number is ranked lower than
55% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. ALOG: 3.37 )
Ranked among companies with meaningful Price/Graham Number only.
ALOG' s Price/Graham Number Range Over the Past 10 Years
Min: 1.04  Med: 1.75 Max: 3.49
Current: 3.37
1.04
3.49
Earnings Yield (Greenblatt) (%) 2.43
ALOG's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. ALOG: 2.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALOG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 3.9 Max: 8.3
Current: 2.43
0.3
8.3
Forward Rate of Return (Yacktman) (%) 5.88
ALOG's Forward Rate of Return (Yacktman) (%) is ranked lower than
57% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.71 vs. ALOG: 5.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALOG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -20.7  Med: 6.25 Max: 33.9
Current: 5.88
-20.7
33.9

More Statistics

Revenue (TTM) (Mil) $508.8
EPS (TTM) $ 0.96
Beta0.73
Short Percentage of Float7.18%
52-Week Range $68.71 - 95.85
Shares Outstanding (Mil)12.45

Analyst Estimate

Jul17 Jul18
Revenue (Mil $) 539 584
EPS ($) 4.02 4.70
EPS w/o NRI ($) 4.02 4.70
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ALOG

Headlines

Articles On GuruFocus.com
Mariko Gordon Sells Stake in Dealertrack Technologies Dec 02 2015 
Mariko Gordon Uses Her Magic Touch and Acquires Holdings in Two Companies Nov 23 2015 
Could These Science Stocks Provide Big Gains? Mar 11 2012 
Weekly Top Insider Buys: Health Care REIT Inc., Human Genome Sciences Inc., Conseco Inc., Universal Jan 02 2010 
Analogic Corp. Reports Operating Results (10-K) Sep 29 2009 
Analogic Corp. (ALOG) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
ETFs with exposure to Analogic Corp. : December 6, 2016 Dec 06 2016
Q1 2017 Analogic Corp Earnings Release - After Market Close Dec 06 2016
ANALOGIC CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 05 2016
BK Ultrasound, Powered by Analogic, Introduces bkFusion at RSNA 2016 Nov 27 2016
Analogic Announces Timing for First Quarter 2017 Earnings Conference Call and Webcast Nov 22 2016
Analogic Announces Timing for First Quarter 2017 Earnings Conference Call and Webcast Nov 22 2016
Analogic Corp. :ALOG-US: Earnings Analysis: 2016 By the Numbers : November 22, 2016 Nov 22 2016
ETFs with exposure to Analogic Corp. : November 15, 2016 Nov 15 2016
Analogic Corp. breached its 50 day moving average in a Bullish Manner : ALOG-US : November 14, 2016 Nov 14 2016
ANALOGIC CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Oct 27 2016
Analogic Announces Leadership Transition Oct 24 2016
Analogic Announces Leadership Transition Oct 24 2016
New Strong Sell Stocks for October 18th Oct 18 2016
BK Ultrasound, Powered by Analogic, Introduces New Premium Cardiac Imaging Software for the bk3500... Oct 14 2016
BK Ultrasound, Powered by Analogic, Introduces New Premium Cardiac Imaging Software for the bk3500... Oct 14 2016
BK Ultrasound, Powered by Analogic, Introduces New Premium Cardiac Imaging Software for the bk3500... Oct 14 2016
ETF’s with exposure to Analogic Corp. : October 12, 2016 Oct 12 2016
Analogic Appoints Mark Laustra to Lead Rollout of New ConneCT Aviation Checkpoint Baggage Screening... Oct 11 2016
BK Ultrasound, Powered by Analogic, Launches the bk3500 Ultrasound System in Europe Oct 07 2016
BK Ultrasound, Powered by Analogic, Launches the bk3500 Ultrasound System in Europe Oct 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)